T cell–specific STAT3 deficiency abrogates lupus nephritis

Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial

(2018) Daniel J Wallace et al.   LANCET

Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study

(2018) Ronald F van Vollenhoven et al.   LANCET

IL-23 Limits the Production of IL-2 and Promotes Autoimmunity in Lupus

(2017) Hong Dai et al.   JOURNAL OF IMMUNOLOGY

Signal transducer and activator of transcription (STAT) 3 inhibition delays the onset of lupus nephritis in MRL/lpr mice

(2015) Lindsay J. Edwards et al.   CLINICAL IMMUNOLOGY

Systemic Lupus Erythematosus

(2011) George C. Tsokos   NEW ENGLAND JOURNAL OF MEDICINE

CXCR4/CXCL12 Hyperexpression Plays a Pivotal Role in the Pathogenesis of Lupus

(2009) A. Wang et al.   JOURNAL OF IMMUNOLOGY

Quantitative and qualitative normal regulatory T cells are not capable of inducing suppression in SLE patients due to T-cell resistance

(2008) MI Vargas-Rojas et al.   LUPUS